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OBJECTIVEdTo test the novel hypothesis that nutritional factors previously associated with
type 1 diabetes etiology or with insulin secretion are prospectively associated with fasting
C-peptide (FCP) concentration among youth recently diagnosed with type 1 diabetes.
RESEARCH DESIGNANDMETHODSdIncluded were 1,316 youth with autoantibody-
positive type 1 diabetes who participated in the SEARCH for Diabetes in Youth study (baseline
disease duration, 9.9 months; SD, 6.3). Nutritional exposures included breastfeeding and age at
introduction of complementary foods, baseline plasma long-chain omega-3 fatty acids including
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), vitamin D, vitamin E, and, from a
baseline food frequency questionnaire, estimated intake of the branched-chain amino acid leu-
cine and total carbohydrate. Multiple linear regression models were conducted to relate each
nutritional factor to baseline FCP adjusted for demographics, disease-related factors, and other
confounders. Prospective analyses included the subset of participants with preserved b-cell
function at baseline (baseline FCP $0.23 ng/mL) with additional adjustment for baseline FCP
and time (mean follow-up, 24.3 months; SD, 8.2; n = 656). FCP concentration was analyzed as
log(FCP).
RESULTSdIn adjusted prospective analyses, baseline EPA (P = 0.02), EPA plus DHA (P =
0.03), and leucine (P = 0.03) were each associated positively and significantly with FCP at follow-
up. Vitamin D was unexpectedly inversely associated with FCP (P = 0.002).
CONCLUSIONSdIncreased intake of branched-chain amino acids and long-chain omega-3
fatty acids may support preservation of b-cell function. This represents a new direction for
research to improve prognosis for type 1 diabetes.
Diabetes Care 36:1842–1850, 2013
A fter clinical diagnosis of type 1 di-abetes, patients commonly retainlimited capacity to secrete insulin
for several months or years (1). Preserva-
tion of b-cell function, measured by
C-peptide concentration (2), has been as-
sociated with lower risk for hypoglycemic
events as well as lower HbA1c and less
frequent microvascular complications
(3). Therefore, identification of interven-
tions to protect against b-cell loss after
onset of type 1 diabetes may improve
prognosis. We hypothesized that nutri-
tional factors previously identified as po-
tentially protective against development
of diabetes autoimmunity or type 1 dia-
betes (4), or those associated with mech-
anisms related to insulin production (5),
also may be useful toward preservation of
b-cell function. The rationale for our hy-
pothesis is based on the notion that the
etiology of type 1 diabetes is multifacto-
rial and that any given protective nutri-
tional factor may not be sufficient to
protect against disease onset but still
may influence disease progression after
clinical diagnosis.
Infant feeding practices, including
breastfeeding (6,7) and timing of intro-
duction of complementary foods (8,9),
have been associated with the develop-
ment of diabetes autoimmunity or type
1 diabetes. Additional work suggests
that vitamins D and E and long-chain
polyunsaturated omega-3 fatty acids
(10,11) may have protective effects
against autoimmune-mediated diabetes.
Branched-chain amino acids, particularly
leucine, can promote insulin secretion
(5), and total carbohydrate intake drives
postprandial glucose excursion and thus
contributes substantially to insulin de-
mand (12). The aim of the present anal-
ysis was to prospectively evaluate each of
these nutritional exposures in relation to
fasting C-peptide (FCP) in a large cohort
of youth with recently diagnosed type 1
diabetes, with ;2 years of follow-up.
Thus, based on published literature, the
following three sets of nutritional expo-
sures were included: reported history of
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infant feeding practices; baseline plasma
biomarkers of selected nutrients; and
baseline estimated intake of selected nu-
trients from a food frequency question-
naire. Results can inform the design of
new studies to establish the efficacy of
nutritional interventions to support
b-cell function in youth with recently di-




Data were derived from the longitudinal
cohort portion of the multicenter
SEARCH for Diabetes in Youth study
and additional data were collected by
the SEARCH Nutrition Ancillary Study
(SNAS), which was designed to test hy-
potheses related to potential nutritional
determinants of sustained b-cell function
among youth with type 1 diabetes. The
parent SEARCH study (13) has ascer-
tained cases of childhood diabetes among
youth younger than age 20 years who
were incident in 2002 or later; ascertain-
ment and data collection are ongoing.
SNASwas funded in 2008, and data collec-
tion was completed in 2011. Both studies
were reviewed and approved annually by
the local institutional review boards that
had jurisdiction over the local study pop-
ulation and complied with the Health In-
surance Portability and Accountability Act.
Data collection
All SEARCH participants who were in-
cident in 2002–2005 and who completed
a baseline study visit were invited for
follow-up visits at ;12 and 24 months
after the baseline visit. Written informed
consent and assent were obtained accord-
ing to the guidelines established by the
local institutional review board at the be-
ginning of each study visit.
Data on treatment regimen, including
type of insulin, total daily insulin dose,
frequency of insulin injections, or use of
continuous subcutaneous insulin infu-
sion (insulin pump), were obtained by
interview with the parent for participants
younger than age 18 years or from the
participants who were 18 years of age or
older. Fasting blood samples were ob-
tained under conditions of metabolic
stability, defined as no episode of diabetic
ketoacidosis during the previous month.
FCP was determined by a two-site immu-
noenzymetric assay (Tosoh AIA; Tosoh
Bioscience, San Francisco, CA). The assay
sensitivity was 0.05 ng/mL. Samples were
analyzed for glutamic acid decarboxylase-
65 (GAD65) and insulinoma-associated-2
(IA-2) diabetes autoantibodies using a
standardized protocol and a common
serum calibrator (14). The cut-off values
for positivity were 33 NIDDK units
(NIDDKU)/mL for GAD65 and 5
NIDDKU/mL for IA-2 (14). HbA1c was
measured in whole blood with an auto-
mated nonporous ion-exchange high-
performance liquid chromatography
system (model G-7; Tosoh Bioscience,
Montgomeryville, PA). Human leukocyte
antigen (HLA) class II genotyping was
performed with a PCR-based sequence-
specific oligonucleotide probe system
(15). HLA genotypes were categorized as
susceptible (DR3/4, DR4/4, DR4/8, DR4/1,
DR 4/13, DR 3/3, DR 3/9, DR 4/9, and DR
9/9 genotypes) and not susceptible (15).
For youth 10 years of age or older,
usual dietary intake was assessed by a
food frequency questionnaire (FFQ)
from a previous week that included foods
to reflect the ethnic and regional diversity
represented by the cohort, as previously
described (16). In brief, the SEARCHFFQ
is semiquantitative, with ;85 food lines
queried for weekly frequency of con-
sumption for each food item. Portion
sizes for each food or beverage are as-
sessed in a manner relevant to that partic-
ular item, e.g., number of eggs or small,
medium, and large for food in bowls
using a two-dimensional food portion vi-
sual. The FFQ was self-administered by
the participant with staff instruction and
support as needed. Parental input was al-
lowed for information the participant was
unable to recall or did not know (e.g.,
type of milk used). The nutrient and
portion-size database for this instrument
was established using the Nutrition Data
Systems for Research database (version
4.05/33, 2002; Nutrition Coordinating
Center, University of Minnesota, Minne-
apolis, MN) and industry sources. Al-
though the FFQ provided data on three
branched-chain amino acids (leucine, iso-
leucine, and valine), we analyzed only
leucine because the correlation among
these three amino acids was so high
(r . 0.95) that unique information
across the three amino acids could not
be discerned.
Data collection
For SEARCH participants with type 1
diabetes diagnosed in 2002–2005, addi-
tional data collected for SNAS included an
infant diet history; using frozen samples
obtained from the baseline SEARCH
examination stored at 2808C, plasma
measures of selected nutrients were ob-
tained including vitamin D, vitamin E,
and fatty acids.
Infant diet history was assessed
through maternal self-report with a ques-
tionnaire modeled after that used by
Norris et al. (17). The questionnaire was
structured as a temporal grid, represent-
ing the child’s age at specific intervals
(first 3 days of life, first week, and each
month through 12 months). In addition
to querying breastfeeding and formula
feeding, respondents were asked when
listed food and beverage items were intro-
duced on a regular basis defined as “at
least once per week.” Infant foods queried
separately include breast milk, formula,
cow milk, soy milk, fruit and fruit juice,
cereals, vegetables, beef, fish, cod liver oil,
and vitamins.
Nutrient biomarkers
The concentration of 25-hydroxyvitamin
D (25-OHD) was measured in plasma
using the direct competitive chemilumi-
nescence immunoassay developed by Dia
Sorin (Stillwater, MN) (UNC detectable
range, 5–320 nmol/L; intra-assay coeffi-
cient of variation, 11.0%) based on a
linkage between specific vitamin D
antibody–coated magnetic particles and
an isoluminol derivative. This method
uses an antibody as a primary binding
agent and measures both 25-OHD2 and
25-OHD3 (18). There were 13 with vita-
min D levels below the detectable limit.
For the purpose of analysis, these values
were imputed as 4.9 nmol/L. Plasma con-
centration of a-tocopherol was assayed
by high-performance liquid chromatog-
raphy using the method of Cheng et al.
(19) (interassay coefficient of variation
,5%).
The utility of the fatty acid profile of
plasma phospholipids to measure dietary
fatty acid intake has been validated rela-
tive to the capacity of these nutrient
biomarkers to predict the specific fatty
acid intake of highly controlled test diets
(20,21). For fatty acid measures, total lip-
ids were extracted from plasma by the
Bligh-Dyer method and phospholipids
were separated from all other lipids by
one-dimensional thin-layer chromatogra-
phy. The phospholipid extract was then
saponified and transmethylated using
the method of Tacconi and Wurtman
(22). Gas chromatography was per-
formed on samples dissolved in unde-
cane using conditions modified from
Lemaitre et al. (23). Data were analyzed
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with ChemStation Firmware A.01.09
(Agilent). The coefficients of variation
(%) in the quality control pool samples
of docosahexaenoic acid (DHA) and eico-
sapentaenoic acid (EPA) were 11.5% and
9.9%, respectively.
Subject inclusion
Included were youth with type 1 diabetes
defined by physicians as type 1, type 1a,
or type 1b diabetes, plus a positive test
for at least one diabetes autoantibody
(GAD65 or IA-2) and baseline measure-
ment of FCP (n = 1,316). For longitudinal
analyses, we restricted the analytic sample
to those who met the Diabetes Control
and Complications Trial–based definition
of preserved b-cell function of FCP
$0.23 ng/mL (1,3) at the baseline exam-
ination and for whom at least one follow-
up value of FCP was available (n = 656).
Thus, the longitudinal analyses specifi-
cally addressed the question of whether
variability in nutritional exposures (early
infant diet or usual diet as of the baseline
visit) predicts variability in follow-up FCP
among those for whom continued preser-
vation of b-cell function was possible. For
individuals with two follow-up FCP val-
ues available, we included only the most
recent value. Sample sizes varied accord-
ing to availability of nutritional exposure
data (Table 1).
Statistical analyses
Initial descriptive analyses were con-
ducted using ANOVA to examine how the
exposures varied according to categories
of baseline FCP (#0.23 ng/mL; .0.23 to
#0.65; and$0.65) to assess the possibil-
ity of threshold effects. Because threshold
effects were not evident (data not shown),
study hypotheses were evaluated using
linear regression to predict FCP, which
was log-transformed to provide better
model fit. Initially, baseline unadjusted
models were fit, followed by models ad-
justed for potential confounders both to
minimize bias in the results and to im-
prove precision of estimates of association.
For consistency, the same potential con-
founders were included in models con-
ducted separately for each nutritional
exposure, with minor exceptions noted.
Potential confounders were variables
shown to be associated with preserved
b-cell function (1) or variables that may
be associated with the nutritional expo-
sures, such as demographics (age, parental
education, race/ethnicity, sex, clinic),
diabetes-related variables (duration, insu-
lin regimen, insulin dose per kilogram,
fasting glucose, HbA1c), and saturated fat
(specifically, plasma saturated fatty acids,
except for models of exposures based on
the FFQ in which saturated fat [grams]
from the FFQ was used). For baseline nu-
tritional exposures derived from the FFQ
(total carbohydrate and leucine), models
were additionally adjusted for total calo-
ries. For vitamin D, models also were ad-
justed for season of the year and for BMI
(z-score) because obese individuals have
lower levels of 25(OH)D than lean indi-
viduals, which may be related to seques-
tering and storage of vitamin D in adipose
tissue (24). To assess consistency between
the baseline and longitudinal samples,
baseline analyses were conducted for the
full analytic sample and were repeated for
the subset of participants included in the
longitudinal analyses.
To address the primary study hypoth-
eses, longitudinal analyses used linear
regression models to predict follow-up
log FCP. Primary results were derived
frommodels that included the same set of
potential confounders used in cross-
sectional models with the additional adjust-
ment for baseline FCP and time between
the baseline and follow-up examinations.
Finally, for both cross-sectional and lon-
gitudinal models, an interaction term
was added to the adjusted models to test for
potential effect modification by HLA risk
group, although it was not retained be-
cause it was not significant in all models.
Statistical significance was established
when P , 0.05.
RESULTSdBaseline characteristics of
participants included in the initial base-
line sample (n = 1,316) and the subset of
those included in the longitudinal anal-
yses (n = 656) are shown in Table 1. By
design, although the full sample included
28.5% of youth with type 1 diabetes who
had already lost all meaningful b-cell
function according to the Diabetes Con-
trol and Complications Trial criteria of
FCP #0.23 ng/mL, all of those included
in the longitudinal subset had preserved
b-cell function at the time of the baseline
examination. At follow-up, 58% of those
in the longitudinal subset had lost b-cell
function.
Table 2 contains the results of the ini-
tial baseline associations for the three sets
of nutritional exposures in relation to
baseline FCP for both the full sample
and the longitudinal subset. Lower
plasma vitamin E was associated with
higher baseline FCP in the adjusted
model in the longitudinal subset only.
Higher plasma EPA was significantly as-
sociated with higher baseline FCP, but
only in the unadjusted model for entire
sample. Higher plasma DHA and the
sum of EPA and DHA were associated
significantly with higher baseline FCP
in both the full sample and in the longi-
tudinal subset, but this cross-sectional
association was not retained after ad-
justment for potential confounders.
From the FFQ, higher estimated intake
of leucine was associated significant-
ly with higher baseline FCP in the un-
adjusted model for the longitudinal
sample.
The results of the longitudinal anal-
yses of associations between each of the
nutritional exposures and follow-up FCP
are presented in Table 3. Surprisingly,
higher levels of plasma vitamin D at base-
line were associated significantly with
lower levels of follow-up FCP, even after
adjustment for covariates. Higher levels
of plasma EPA, DHA, and their sum at
baseline were each associated with sig-
nificantly higher follow-up FCP in un-
adjusted models (all P# 0.01). After
adjustment for potential confounders,
EPA and the sum of EPA and DHA re-
mained significantly positively associ-
ated with follow-up FCP (P = 0.02 and
0.03, respectively). Participants with
higher estimated intake of leucine at
baseline had higher follow-up FCP after
adjustment for potential confounders
(P = 0.03).
To put the statistically significant
findings in the clinical context in which
the average change in FCP in the longi-
tudinal subset was a decrease of 57%
(Table 1), we estimated the difference in
follow-up FCP that would be predicted
by a 1-SD difference in the nutritional ex-
posure at baseline after adjustment for
confounding. Unexpectedly, a 1-SD
higher baseline plasma vitamin D level
was associated with a 12.6% lower FCP
at follow-up. Consistent with the hypoth-
esized effects, a 1-SD higher plasma EPA
level and EPA plus DHA level at baseline
were associated with 9.2% and 8.9%
higher follow-up FCP, respectively. A
1-SD higher estimated intake of leucine
was associated with 5.7% higher follow-
up FCP.
CONCLUSIONSdFrom a large, di-
verse cohort of youth with type 1 diabetes
confirmed by the presence of diabetes
autoimmunity, findings suggest that se-
lected nutritional factors may act either to
enhance or to reduce b-cell decline over a
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(baseline FCP .0.23 ng/mL)
N Mean (SD) or % N Mean (SD) or %
Demographic and clinical characteristics
Age, years 1,316 11.1 (4.0) 656 11.5 (3.7)
Race/ethnicity
Non-Hispanic white 1,025 77.9 513 78.2
African American 121 9.2 59 9.0
Hispanic 143 10.9 73 11.1
Asian/Pacific Islander 15 1.1 6 0.9
American Indian 6 0.5 2 0.30
Other 6 0.5 3 0.5
Sex, % female 642 48.8 311 47.4
Parental education
Less than high school 56 4.3 25 3.8
High school graduate 188 14.4 86 13.2
Some college/Associate’s degree 440 33.6 226 34.6
Bachelor’s degree or more 624 47.7 316 48.4
Diabetes duration at initial visit, months 1,316 9.9 (6.3) 656 7.9 (5.6)
Insulin regimen
Pump 114 8.8 47 7.3
Long + short/rapid insulin, $3 times/day 409 31.5 235 36.4
Long + any other combination, $2 times/day 90 6.9 36 5.6
Any combination of insulin excluding long,
$3 times/day 198 15.3 89 13.8
Any insulin used once/day or any insulin
combination excluding long, twice/day 486 37.5 239 37.0
Insulin dose, units/kg 1,257 0.64 (0.32) 634 0.56 (0.3)
HbA1c, % 1,310 7.72 (1.53) 654 7.4 (1.3)
Fasting glucose, mg/dL 1,308 171 (77) 653 156.9 (65)
BMI z-score 1,281 0.56 (0.97) 641 0.61 (0.95)
Fasting C-peptide
Baseline FCP, ng/mL 1,316 0.69 (0.65) 656 0.91 (0.7)
Follow-up FCP, ng/L 909 0.31 (0.40) 656 0.37 (0.44)
Change in FCP from baseline until
follow-up, ng/mL 909 20.40 (0.59) 656 20.53 (0.63)
Percent change in FCP from baseline
until follow-up 909 241.9 (90.9) 656 257.4 (37.8)
Baseline FCP category, ng/mL
#0.23 375 28.5 0 0
.0.23– 0.65 440 33.4 307 46.8
.0.65 501 38.1 349 53.2
Follow-up fasting C-peptide category, ng/mL
#0.23 613 67.4 378 57.6
.0.23–0.65 181 19.9 168 25.6
.0.65 115 12.7 110 16.8
Infant feeding exposures
Breastfeeding
Never 259 28 136 26.9
,6 months 275 29.8 155 30.7
$6 months 390 42.2 214 42.4
Age at introduction of complementary
foods, months
Any solid food 960 4.64 (2.11) 524 4.62 (2.17)
Any dairy (including formula) 870 4.89 (4.24) 468 4.71 (4.18)
Continued on p. 1846
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period of;2 years after clinical diagnosis
of type 1 diabetes. Unexpectedly, baseline
plasma concentration of vitamin D was
associated inversely with FCP concentra-
tion at follow-up. However, consistent
with study hypotheses, intake of long-
chain omega-3 polyunsaturated fatty
acids and branched-chain amino acids
may prospectively support sustained
b-cell function.
As previously reported from the
SEARCH cohort, we have shown that
among individuals with diabetes who are
positive for diabetes autoimmunity, youn-
ger age at diagnosis, non-Hispanic white
race/ethnicity, male sex, higher baseline
HbA1c, and lower baseline BMI z-score
were independently associated with signifi-
cantly lower baseline FCP level (25). The
predicted rate of decline in FCP levels
among these youth was 4.1% (95% CI,
3.9–4.3) per month, regardless of age at
diagnosis, sex, race/ethnicity, and HLA
risk status. When baseline diabetes auto-
antibodies positivity status was added to
the model, the presence of two diabetes
autoantibodies versus one diabetes auto-
antibody was the only variable signifi-
cantly associated with faster decline in
FCP levels (P , 0.0001): estimated 4.4%
per month (95% CI, 4.1–4.7) in those
with double autoantibody positivity ver-
sus 3.7% per month (95% CI, 3.4–4.0)
in those with single autoantibody positiv-
ity. This suggests that factors that impact
on the underlying autoimmune processes
may, in turn, impact on rate of b-cell de-
cline. The present finding demonstrates
that selected nutritional factors may be
important.
Across exposures, occasional differ-
ences were observed between baseline
and prospective analyses. We focus at-
tention on results from the prospective
analyses for three reasons. First, this is
consistent with the SNAS a priori hypoth-
eses and study design. Second, inclusion
of baseline FCP in the prospective anal-
yses allowed for improved precision by
accounting, at least in part, for other
unmeasured factors that impact directly
on both baseline and follow-up FCP in
individuals, such as genetics or other
biological determinants of FCP and
change in FCP. Third, the correct tempo-
ral sequence is established in the pro-
spective analyses, whereas this is not true
of the baseline analyses.
Infant feeding exposures
Infant feeding may contribute to the de-
velopment of type 1 diabetes, but the
research evidence is equivocal (6,7) and
may depend on genetic susceptibility
(26). In the current study, we found no
evidence that breastfeeding was asso-
ciated with FCP at either baseline or
follow-up. We also evaluated the timing
of introduction of selected foods to the
infant diet because these may alter risk
for autoimmunity and type 1 diabetes
(8,9,27), although again the literature is
mixed and our findings were negative.
Baseline nutritional exposures:
biomarkers
Cod liver oil in infancy has been inversely
associated with type 1 diabetes (10),
which could reflect a protective effect of
one or more of the major constituents of
cod liver oil, i.e., vitamin D and the
omega-3 fatty acids derived from fish, in-
cluding EPA and DHA. Vitamin D or ge-
netic variations of the vitamin D receptor
may protect against inflammation and au-
toimmunity (28); however, studies fo-
cused on type 1 diabetes have yielded
mixed results (29,30). Unexpectedly, in
our longitudinal analyses, baseline
plasma vitamin D was significantly in-
versely associated with follow-up FCP.
Results were verified by review of unad-
justed scatter plots, confirmation of
model fit, and evaluation of potential ef-
fect modifiers (BMI, duration of diabe-
tes, baseline FCP, and HLA), and the
finding of an inverse association was
confirmed. Our study was limited in
that measurement of the active form of
vitamin D [1, 25(OH)2D3] is not feasible
in epidemiologic studies, and we did not
have measures of variation in the vita-
min D receptor and other vitamin D me-
tabolism genes. Of note, two small
clinical trials failed to demonstrate ben-
efit of vitamin D supplementation on
sustained b-cell function (31,32); thus,
taken together with our findings, it is
unlikely that vitamin D improves
b-cell preservation.
The role of EPA and DHA on immune
function appears to differ substantially
according to disease state, such that
studies of disease-specific outcomes are
required (33). Animal models show pro-
tection by these fatty acids against
development of type 1 diabetes (34);
however, a recent study of nutritional sta-
tus in a large cohort of youth failed to




(baseline FCP .0.23 ng/mL)
N Mean (SD) or % N Mean (SD) or %
Any vegetable (excluding potatoes) 929 6.55 (2.16) 505 6.57 (2.18)
Gluten-containing cereal 935 6.81 (2.75) 515 6.85 (2.8)
Baseline nutritional exposures: biomarkers
Vitamin D (plasma 25-OHD), nmol/L 1,145 58.3 (33.4) 591 60.0 (34.6)
Vitamin E (plasma a-tocopherol), mg/mL 1,005 6.2 (3.04) 520 5.94 (2.82)
EPA, plasma phospholipid percent weight 820 0.41 (0.25) 398 0.42 (0.27)
DHA, plasma phospholipid percent weight 827 2.45 (0.83) 400 2.45 (0.84)
EPA + DHA 820 2.86 (0.97) 398 2.87 (1.01)
Baseline nutritional exposures: estimated intake from FFQ
Leucine, g/1,000 kcal, from FFQ* 730 3.21 (0.51) 397 3.24 (0.5)
Carbohydrate, g/1,000 kcal, from FFQ* 730 115.9 (18.3) 397 115.0 (18.2)
SEARCH 2002–2005 incident case analytic sample (n = 1,316) and the subset of those included in longitudinal analyses (n = 656) with baseline FCP$0.23 ng/mL and
follow-up data available. *FFQ administered to youth 10 years of age or older.
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autoimmunity (35). However, signifi-
cantly reduced risk of development of is-
let autoimmunity was associated with
increased intake of omega-3 fatty acids
among youth genetically susceptible to
development of type 1 diabetes (36),
although continued follow-up did not
reveal subsequent protection against in-
cident type 1 diabetes (37). Our study
suggests that long-chain omega-3 fatty
acids may provide protection to the
b-cell after clinical diagnosis of type 1
diabetes.
Current nutritional exposures:
estimated intake from FFQ
Leucine and other branched-chain amino
acids have been shown to stimulate in-
sulin secretion through multiple effects
on b-cell function (5), as demonstrated in
models of type 2 diabetes and in healthy
humans. Whether any of these mecha-
nisms are relevant to the capacity of
b-cells to continue to produce insulin
during the autoimmune process of type
1 diabetes has not been evaluated. Our
results support further study of the
potential role of branched-chain amino
acids to enhance sustained insulin pro-
duction in type 1 diabetes.
Strengths and limitations
SEARCH and SNAS have considerable
strengths, including the availability of
detailed nutritional data regarding a large
cohort of well-characterized youth with
type 1 diabetes and the capacity to eval-
uate the hypothesized associations in a
prospective design. However, because
SEARCH is a large epidemiologic study,
Table 2dCross-sectional associations of nutritional exposures with log fasting C-peptide for SEARCH 2002–2005 incident cases and the




All cases N = 1,316† N = 656†
Model Beta coefficient (SE) P Beta coefficient (SE) P
Infant feeding exposures
Breastfeeding Unadjusted 0.26 (overall)‡ 0.70 (overall)‡
Never 0.10 (0.07) 0.06 (0.07)
,6 months 0.09 (0.07) 0.02 (0.06)
$6 months 0 (referent) 0 (referent)
Adjusted 0.051 (overall)‡ 0.43 (overall)‡
Never 0.15 (0.07) 0.06 (0.08)
,6 months 20.03 (0.07) 20.05 (0.08)
$6 months 0 (referent) 0 (referent)
Age at introduction of complementary food, months
Any solid food Unadjusted 20.014 (0.013) 0.29 0 (0.012) 0.97
Adjusted 0.006 (0.013) 0.67 0.026 (0.014) 0.07
Any dairy (including formula) Unadjusted 20.0073 (0.0069) 0.29 0.0001 (0.0068) 0.99
Adjusted 20.0031 (0.007) 0.65 0.011 (0.0079) 0.16
Any vegetable (excluding potatoes) Unadjusted 20.0063 (0.0131) 0.63 0.0035 (0.0125) 0.78
Adjusted 0.0073 (0.013) 0.57 0.0181 (0.0138) 0.19
Gluten-containing cereal Unadjusted 0.0083 (0.0102) 0.41 0.0052 (0.0096) 0.59
Adjusted 0.0167 (0.0101) 0.10 0.0192 (0.0108) 0.08
Baseline nutritional exposures: biomarkers
Vitamin D (plasma 25-OHD), nmol/L Unadjusted 20.0013 (0.0008) 0.10 20.0015 (0.0007) 0.05
Adjusted 0.0014 (0.0008) 0.07 0.0008 (0.0008) 0.30
Vitamin E (plasma a-tocopherol), mg/mL Unadjusted 20.015 (0.009) 0.11 20.013 (0.01) 0.18
Adjusted 20.014 (0.008) 0.09 20.024 (0.01) 0.01
EPA, plasma phospholipid percent weight Unadjusted 0.231 (0.117) 0.049 0.067 (0.11) 0.54
Adjusted 0.03 (0.096) 0.75 20.019 (0.098) 0.84
DHA, plasma phospholipid percent weight Unadjusted 0.088 (0.0346) 0.01 0.0897 (0.0354) 0.01
Adjusted 0.017 (0.03) 0.57 20.002 (0.033) 0.96
EPA + DHA Unadjusted 0.078 (0.030) 0.008 0.068 (0.030) 0.02
Adjusted 0.014 (0.033) 0.58 20.0026 (0.027) 0.93
Baseline nutritional exposures: estimated intake from FFQ
Leucine, g/1,000 kcal, from FFQ Unadjusted 0.053 (0.033) 0.11 0.071 (0.035) 0.04
Adjusted 0.036 (0.03) 0.23 0.039 (0.036) 0.28
Carbohydrate, g/1,000 kcal, from FFQ Unadjusted 20.0005 (0.0009) 0.57 20.0013 (0.001) 0.17
Adjusted 20.0006 (0.0011) 0.59 20.0008 (0.0013) 0.54
*Adjusted model includes demographics (age, parental education, race, sex, clinic), diabetes-related variables (duration, insulin regimen, insulin dose per kg, fasting
glucose, HbA1c), and saturated fat (plasma saturated fatty acids, except for models of exposures based on the FFQ in which saturated fat [grams] from the FFQ was
used). †Sample size varies by exposure and model covariates. ‡Step-down tests for breastfeeding history are not provided because the overall tests are not significant.
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we used fasting, rather than stimulated,
C-peptide levels to assess b-cell function.
Although FCP correlates well with stimu-
lated C-peptide (38), future studies would
benefit from use of outcomes derived from
standardized mixed meal–stimulated
C-peptide. Exposure assessment was im-
perfect, partly because of reliance on recall
by mothers (for infant feeding) or self-
report for baseline dietary intake. How-
ever, recall bias is unlikely given that
nutrition is not a commonly recognized
correlate of FCP among youth with estab-
lished type 1 diabetes. Further, although
analyses adjusted for diabetes duration
and length of follow-up, the baseline
assessmentwas not completed immediately
on diagnosis, and duration of follow-
up was variable. It does not seem likely
that bias would result from these time-
related design issues; however, somedegree
of precision may have been lost. Finally,
despite the study a priori hypotheses driven
by biologic plausibility and previous litera-
ture, the observed statistically significant
findings may be attributable to chance. Our
findings suggest that selected nutritional
factors, particularly intake of long-chain
omega-3 fatty acids and branched-chain
amino acids, may have a positive impact
on b-cell function in a clinically relevant
manner. Mechanisms may relate to those
postulated for development of diabetes-
related autoimmunity or incidence of type
1 diabetes, or may be unique to the natural
history of b-cell failure in the face of auto-
immunity after clinical diagnosis of type
1 diabetes. These novel results can be
used to design future studies to establish
the efficacy and effectiveness of nutritional
approaches to support preservation of
b-cell function among youth with recently
diagnosed type 1 diabetes.
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